Biological beauty presents the challenge and opportunity to innovate in categories that go beyond superficial aesthetics, delving into health, emotional intelligence, and long-term prevention.
Regenerative Aesthetics Market: This specific sector will surpass 28.75 billion to 29 billion dollars by the year 2030, growing at an accelerated rate of 13% to 13.2% annually. To put it into perspective, regenerative aesthetics will come to represent approximately 30% of the total dermatological drugs market.
It is estimated that, between 2025 and 2030, exosome-based therapies will contribute 4 billion dollars to market growth, while other products (such as PRP and biostimulators) will contribute an additional 9 billion dollars. By 2030, these “other products” will remain the largest segment, representing 69% (20 billion dollars) of the total regenerative market.
According to the International Society of Aesthetic Plastic Surgery (ISAPS), over 19 million non-surgical procedures (such as injectables and biostimulators) and more than 14 million aesthetic surgeries have been performed worldwide in the last analyzed year.
The ultimate fusion: Beauty, Wellness, and Neurocosmetics
The traditional “anti-aging” approach has been replaced by skin longevity and metabolic health. The products of 2026 seek to optimize functioning at the cellular level, treating the skin and hair as biomarkers of the consumer’s internal physiological state. For Latin American formulators, this represents an opportunity to integrate advanced ingredients such as exosomes, peptides, spermidine, and NAD+ precursors into daily-use cosmetics.
Furthermore, the beauty experience has transformed into a nervous system management tool through neurocosmetics. By using adaptogenic extracts and functional fragrances, manufacturers can create scientifically designed products to reduce cortisol levels, stimulate dopamine, and calm stress-induced skin inflammation.
The Impact of GLP-1 drugs on cosmetic development
The massive adoption of weight-loss medications (like Ozempic or Wegovy) has led to two critical market trends for the B2B sector:
- Skincare for “Ozempic Face”: Rapid fat loss causes sagging and a “sunken” facial appearance. This opens a formulation niche for volumizing topicals and biostimulators that use PDRN, spicules, and high-performance peptides to mimic the filling effect of adipose tissue and stimulate collagen.
- The “Fauxzempic” Movement: Geared toward the wellness-centric consumer who avoids pharmaceuticals. This category demands the manufacturing of lymphatic drainage creams, anti-inflammatory serums, and body wraps that promote aesthetic sculpting and toning results backed by active ingredients, without the need for medical prescriptions.
Ingestible beauty: The hybridization of personal care
The boundaries between cosmetics and supplement aisles have completely disappeared. The 2026 market demands that manufacturers adopt the “beauty from the inside out” concept, creating routines where gut health, hormonal balance, and skin appearance are treated as a single interconnected system.
Manufacturers must prepare for a boom in nutricosmetics and ingestible beauty, integrating magnesium gummies, collagen supplements, NAD+ precursors, and adaptogens into their portfolios. Commercial success will lie in offering hybrid solutions. For example, product lines that combine a topical-use serum with an ingestible supplement to maximize cellular regeneration.
The manufacturing and packaging context in Latin America
For Latin American manufacturers to capitalize on these advanced formulation trends, they must overcome specific regional dynamics in their supply chains and packaging. According to recent studies, plastic circularity in Latin America continues to face financing gaps, infrastructure weaknesses, and regulatory voids that can undermine sustainable progress.
Facing these challenges, the regional industry is seeking viable alternatives for mass production. An expansion in key supply chain initiatives is observed, such as the increase in the distribution of PET caps in Latin America, driving more responsible packaging options.
Is it better to formulate with collagen inducers or bet on genetic cellular reprogramming?
For immediate, proven, and accessible clinical results today, it is better to formulate with collagen inducers. However, to lead the future of long-term anti-aging medicine, the ultimate bet is genetic cellular reprogramming.
For manufacturers in the region, adapting to circular economy models through refillable packaging, mono-materials, and the proactive use of PCR (post-consumer recycled) plastics will be crucial to offset the lack of local recycling infrastructure and remain competitive in the face of demands from an environmentally conscious global consumer.
Should we prioritize natural biomimetic peptides over traditional synthetic ones?
Yes. It is preferable to prioritize natural biomimetic peptides (of botanical origin) because the skin identifies them as its own, which guarantees greater compatibility and activates comprehensive and long-lasting cellular regeneration. In contrast, traditional synthetic peptides often offer limited effects and are not always recognized by cells.
Can we create formulations that act at the epigenetic level to “reset” cellular age?
Yes. The use of botanical ingredients and RNA-based tools (such as microRNAs or Yamanaka factors) is currently being researched to modify genetic expression and “reset” the cell’s biological clock without altering the DNA sequence.
For B2B companies in the region, 2026 marks the end of beauty as a purely aesthetic correction. The manufacturers in Latin America who will lead the next decade will be those who understand beauty as a branch of biological preventive medicine, develop highly effective hybrid formulations (GLP-1, ingestibles, and neurocosmetics), and strategically navigate the circularity challenges in the region to offer holistic and sustainable products.
No te conformes con leer estos informes.
Accede a la inteligencia Mercado Exclusiva
Únete al Círculo Privado para que seas parte de la Inteligencia de Mercado B2B